

Rec'd PCT/PTO 09 MAR 2005  
PC 121 83/89 6042  
09.10.03



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 20 OCT 2003

WIPO

PCT

Bescheinigung

Certificate

Attestation

EP/03/8687

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

02078707.3

**PRIORITY  
DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

Der Präsident des Europäischen Patentamts;  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

R C van Dijk

BEST AVAILABLE COPY



Europäisches  
Patentamt

1211E1 020707.3  
Euro  
Patent Office

Office européen  
des brevets

09.10.03

Anmeldung Nr:  
Application no.: 02078707.3  
Demande no:

Anmeldetag:  
Date of filing: 09.09.02  
Date de dépôt:

Anmelder/Applicant(s)/Demandeur(s):

NESTEC S.A.  
Avenue Nestlé 55  
CH-1800 Vevey  
SUISSE

Bezeichnung der Erfindung/Title of the invention/Titre de l'invention:  
(Falls die Bezeichnung der Erfindung nicht angegeben ist, siehe Beschreibung.  
If no title is shown please refer to the description.  
Si aucun titre n'est indiqué se référer à la description.)

Orally administrable compositions for improving skin quality

In Anspruch genommene Priorität(en) / Priority(ies) claimed / Priorité(s)  
revendiquée(s)  
Staat/Tag/Aktenzeichen/State/Date/File no./Pays/Date/Numéro de dépôt:

Internationale Patentklassifikation/International Patent Classification/  
Classification internationale des brevets:

A61K31/00

Am Anmeldetag benannte Vertragsstaaten/Contracting states designated at date of  
filing/Etats contractants désignées lors du dépôt:

AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

## Orally administrable composition for improving skin quality

The present invention pertains to a method for improving skin quality, in particular by preventing or reversing signs of skin aging in humans or animals. The present invention also relates to substances and/or compositions stimulating extracellular matrix production in skin.

### Background of the Invention

During the lifetime of a living being different signs, characteristic of aging, appear on the skin, with the principal clinical signs being the appearance of fine lines and deep wrinkles which increase or are accentuated with age. Moreover, the skin's complexion is generally modified and diffuse irritations and occasionally telangiectasias may come into existence on certain areas. These signs of ageing are even promoted by exposure of the skin to exogenous influences, such as e.g. UV-radiation, pollutants, free radicals or chemical substances.

Skin aging is reflected by major structural changes and variations in composition. Most notably aged skin has less collagen and glycosaminoglycans compared with young skin (Fenske NA, Lober CW: J Am Acad Dermatol 15:571-85 1986).

On the molecular level the connective tissue is predominantly composed of collagens, proteoglycans and hyaluronic acid. While the collagens form a basket like three-dimensional mesh, the proteoglycans are embedded within. Proteoglycans are composed of a core protein to which numerous glycosaminoglycan side chains, repeating non-branched disaccharides, are covalently attached. One component of the disaccharide unit is an aminosugar hence the name GAG. The amount of carbohydrate in a proteoglycan can comprise up to 95% of its weight. Concomitant is the huge water binding capacity of proteoglycans. In skin these molecules compartmentalize interstitial fluid water in the dermis. Their swelling properties within the collagen meshwork build up an internal pressure which smoothes the skin surface and generates the skin turgor.

Several attempts have been made to inhibit the aging process or even revert the occurred alterations. Topical application of pharmacological substances or cosmetic ingredients to date has produced best results. In this respect FR 2808682 provides a novel cosmetic product especially for skin care, which contains fresh, polyphenol-containing vine cells as active agent, together with a carrier suitable for topical application.

Also, DE 10108097 provides a cosmetic formulation, especially for use on aging and/or stressed skin, which contains water and substance(s) forming lamellar structures with water, also contains compound(s) (I) with trimethylammonium-methyl group(s) of formula (IA), metabolites of (I) and/or S-adenosylmethionine.

US 2002/0041890 discloses cosmetic skin care methods and compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof. These compositions provide control of sebum secretion from sebocytes, improved oil control and improved skin feel, prevent shine and stickiness, while also providing anti-aging benefits which results in reduced appearance of wrinkles and aged skin, improved skin colour, treatment of photoaged skin, improvement in skin's radiance and clarity and finish, and an overall healthy and youthful appearance of the skin.

Another means to prevent skin deterioration or ageing, respectively, is to provide compounds scavenging free radicals. In this respect EP 0 761 214 discloses singlet oxygen quenchers comprising aniline derivatives and difurfuryl amine derivatives, which are reported to reduce the oxidative stress to the skin.

Some medicaments have also been developed in this regard. For example, EP 1230952 provides a method of preparing a medicament comprising an estrogen and a progestogen for use in delaying the onset and treating skin aging.

On the other hand, few dietary compositions have already been described. In US 6365175, edible compositions containing petroselinic acid are used for the

preparation of food compositions or food supplements that are used as anti-inflammatory compositions that inhibit the production of metabolites of arachidonic acid and/or reduces the formation of intracellular adhesion molecules or as anti-aging compositions with a positive impact on wrinkling, sagging, photodamaged skin, dry skin, flaky skin and age spots.

There is still a need in the art to provide an effective nutritional way for improving skin quality and preventing or reverting alterations due to aging process.

Accordingly, an object of the present invention is to provide such means in order to improve skin quality.

This problem has been solved by providing orally administrable compositions, that are capable to stimulate extracellular matrix production, particularly synthesis of components such as glycosaminoglycans that bind interstitial fluid and thus improve skin turgor.

#### Summary of the Invention

Accordingly, in a first aspect the present invention aims to provide an orally administrable composition for improving skin quality in humans or animals, which comprises as an active ingredient an effective amount of a molecule that stimulates energy metabolism of the cell, an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier.

Such a composition further prevents or restores skin age-related alterations in humans or animals.

Indeed, it has been surprisingly found that nutrients such as some molecule that stimulate energy metabolism such as carnitine, and also antioxidants, e.g. ginkgo extracts can stimulate production and deposition in skin of glycosaminoglycans, thus improving skin turgor .

The composition may be a complete and nutritionally balanced food for human or animal. It can also be a dietary supplement, a pharmaceutical or veterinary composition, for example.

5           The composition according to the present invention can prevent or delay alterations occurring during skin aging. It can also provide multiple benefits by improving skin hydratation, skin elasticity, skin appearance, and reduce or revert skin dryness, wrinkling, pore size and skin roughness.

10           In another aspect, this invention relates to the use of an effective amount of a molecule that stimulates energy metabolism of the cell, an antioxidant or combinatory admixtures thereof, for the preparation of a composition intended to improve skin quality and prevent or restore skin age-related alterations in humans or animals.

15           In a further aspect, this invention provides a method to improve skin quality and prevent or restore age-related alterations of skin in humans or animals, comprising administering to the individual, an orally administrable composition as described above.

20

#### Detailed Description of the Invention

          According to the first aspect, an orally administrable composition for improving skin quality, which comprises as an active ingredient an effective amount  
25           of a molecule that stimulates energy metabolism of the cell, an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier, is concerned.

          The molecule that stimulates energy metabolism of the cell may be L-carnitine, creatine, fatty acids (mono or polyunsaturated fatty acids, particularly  
30           omega-3 fatty acids), cardiolipin, nicotinamide, carbohydrate and natural sources thereof, for example.

Preferably, the amount of said molecule is of at least 1mg per kg of body weight per day, more preferably from 1mg to 1 g per kg of body weight per day.

The antioxidants are compounds that decrease protein oxidation (e.g. prevent  
5 formation of protein carbonyls). They may be sources of thiols (e.g. Lipoic acid, cysteine, cystine, methionine, S-adenosyl-methionine, taurine, glutathione and natural sources thereof), or compounds that upregulate their biosynthesis in vivo, for example. The antioxidant according to the invention may also be other antioxidants such as vitamin C, vitamin E (tocopherols and tocotrienols), carotenoids (carotenes,  
10 lycopene, lutein, zeaxanthine..) ubiquinones (e.g. CoQ10), tea catechins (e.g. epigallocatechin gallate), coffee extracts containing polyphenols and/or diterpenes (e.g. kawheol and cafestol), ginkgo biloba extracts, grape or grape seed extracts rich in proanthocyanidins, spice extracts (e.g. rosemary), soy extracts containing isoflavones and related phytoestrogens and other sources of flavonoids with  
15 antioxidant activity, compounds that upregulate cell antioxidant defense (e.g. ursodeoxycholic acid for increased glutathione S-transferase, ursolic acid for increased catalase, ginseng and ginsenosides for increase superoxide dismutase and natural sources thereof i.e. herbal medicines).

20 Preferably, the amount of the antioxidant is of at least 0.025 mg per kg of body weight per day, more preferably from 0.025 mg to 250mg per kg of body weight per day.

The carrier may be any food or pharmaceutical product, or a nutritional  
25 supplement or a composition for oral administration. Examples for food or pharmaceuticals carriers are milk, yoghurt, curd, cheese, fermented milks, milk based fermented products, ice-creams, fermented cereal based products, milk based powders, infant formulae or tablets, liquid suspensions, dried oral supplement, wet oral supplement, dry-tube-feeding, pet food products. The composition for oral  
30 administration may be in capsules, soft capsules, tablets, pastes or pastilles, gums, or drinkable solutions or emulsions. Methods for preparing the carrier are common knowledge.

The composition according to the invention may also comprise usual excipients, in particular sweeteners, flavouring agents or preservatives. It can further comprise a prebiotic and/or a probiotic microorganism.

5           The compositions of the invention may be formulated according to any technique that is well known to this art.

10           In one embodiment, a pharmaceutical composition containing at least one of the active components in an amount sufficient to achieve the desired effect in an individual can be prepared. This composition may be a tablet, a liquid, a dried oral supplement, a wet oral supplement, dry tube-feeding, wet tube-feeding etc.. The pharmaceutical composition will further contain carriers and excipients that are suitable for delivering the respective active molecule of different nature to the target tissue. The kind of the carrier/excipient and the amount thereof will depend on the  
15           nature of the substance and the mode of drug delivery and/or administration contemplated. It will be appreciated that the skilled person will, based on his own knowledge select the appropriate components and galenic form to target the active compound to the skin.

20           In another embodiment, a food composition for human consumption is prepared. This composition may be a nutritional complete formula, a dairy product, a chilled or shelf stable beverage, soup, a dietary supplement, a meal replacement, and a nutritional bar or a confectionery.

25           The nutritional formula is preferably enterally administrable; for example in the form of a powder, a liquid concentrate, or a ready-to-drink beverage. If it is desired to produce a powdered nutritional formula, the homogenised mixture is transferred to a suitable drying apparatus such as a spray drier or freeze drier and converted to powder.

30

          In another embodiment, a usual food product may be enriched with the combination according to the present invention. For example, a fermented milk, a yoghurt, a fresh cheese, a renneted milk, a confectionery bar, breakfast cereal flakes



or bars, drinks, milk powders, soy-based products, non-milk fermented products or nutritional supplements for clinical nutrition. Then, the amount of the molecule that stimulates energy metabolism is preferably of at least 50 ppm by weight and can be up to 2000 mg per day and the antioxidant is preferably of at least 10 ppm by weight.

In a further embodiment, pet food products may be prepared. The petfood formulation is preferably a complete and nutritionally balanced pet food. It can also be a dietary supplement for pets or in the form of a pharmaceutical composition. The nutritionally complete pet food formulation according to the invention may be in any suitable form, for example a powder, a dried kibble, or pellet or other dried form, extruded form, semi-moist or wet form, such as a chunk or loaf or pudding. It may be chilled or provided as a shelf stable product. This pet food may be produced by conventional methods.

In another embodiment, dietary supplements may be prepared so as to improve pet food quality. As dietary adjuncts, they may be encapsulated or may be provided in powder form and packaged in conjunction with or separately from a main meal, be it wet or dry. By way of example, a powder containing selected substances according to the invention, may be packed in sachets in a powder form or in a gel or lipid or other suitable carrier. These separately packaged units may be provided together with a main meal or in multi-unit packs for use with a main meal or treat, according to user instructions.

The food composition according to the present invention aims to improve skin hydration, skin elasticity, skin appearance, and reduce or revert skin dryness, wrinkling, pore size and skin roughness.

According to another aspect, this invention relates to the use of a (list of compounds used will be added if OK), for the preparation of an orally administrable composition intended to improve skin quality and prevent or restore age-related alterations in humans or in animals.

According to a last aspect, this invention provides a method to improve skin quality and prevent or restore age-related alterations of skin in humans or animals, comprising administering to the individual, a composition as described above.

5           The said composition may be administered to the mammal as a supplement to the normal diet or as a component of a nutritionally complete food. It is preferred to prepare a nutritionally complete food as described above.

10           Preferably, the amount of the composition to be consumed by the individual to obtain a beneficial effect will depend upon its size, its type, and its age. However an amount of carnitine of at least 1mg per kg of body weight per day and an amount of the antioxidant of at least 0.025 mg per kg of body weight per day, would usually be adequate.

15           The following examples are given by way of illustration only and in no way should be construed as limiting the subject matter of the present application. All percentages are given by weight unless otherwise indicated.

20           **Example 1: In-vivo trials on the effect of dietary nutrients according to the present invention.**

• **Study design:**

Dietary intervention was of 3 months, all animal groups were fed Ad lib. Animal weight was measured once a week.

25

• **Animals:**

Male mice C57/BL6 were obtained from Iffa credo (France) at 9 weeks of age. After 3 weeks adaptation, mice (12 weeks old) were housed individually and fed the control diet until the nutritional intervention. At 12 months of age the mice were randomised in 5 groups (A, C, D, E and F) of 10 mice. Dietary intervention was of 3 months; mice had free access to food and water and were submitted to 12 hours light and dark cycles.

30

- **Diets:**

The control diet (diet A) composed of 18% proteins (soy and whey), 11% fat (soybean oil), 59% carbohydrates (starch + sucrose) and 10% cellulose was supplemented with either ginkgo biloba extract (diet E), or a cocktail of antioxidants comprising vitamin C, vitamin E, grape seed extract and cysteine (diet C) and/or L-carnitine (diet D and F respectively). These diets are as follows:

**Diet A - Control :** 18% proteins (soy and whey), 11% fat, 59% carbohydrates, 5% cellulose.

**Diet C - Cocktail of antioxidants :** Diet A + 0.19% vit C, 0.03% vit E, 0.075% grape seed extract, 0.4% cysteine.

**Diet D :** Diet A + 0.3% L- carnitine + cocktail of antioxidants of diet C.

**Diet E :** Diet A + 0.0375% Ginkgo biloba extract (Linnea)

**Diet F :** Diet A + 0.3% L- carnitine

- **Glycosaminoglycan determination:**

After three month of dietary intervention the animals were sacrificed and standardised biopsies taken. Dorsal skin (midline, lower back) was collected freed from coat hair weighed, minced to 0.5 x 0.5 mm squares. These were extracted in 10 times volume of their weight for 24 hours in 0.1% acetic acid, 1 M NaCl at 40C with constant agitation. The samples were clarified from insoluble matter (remaining coat hair, epidermis) by centrifugation yielding an upper lipid layer, aqueous layer containing dissolved dermis and a pellet with insoluble matter. The aqueous layer was saved and protein determined. 25 microliter of this supernatant were supplemented with 200 microliter BCA reagent (BCA reagent A premixed with BCA reagent B according to the manufacturer's instructions, Pierce, Rockford, IL, USA) and incubated for 30 seconds with constant agitation. Colour development was measured at 562 nm protein concentration calculated from a BSA standard curve.

Glycosaminoglycans were determined in the extract according to the protocol of Chandrasekhar et al., Anal. Biochem. 161:103-108 1987). 50 microliter of the extract were mixed with 200 microliter of DMB reagent (19 mg dimethylene blue,

2.0 ml formic acid, 2.0 g Na-formate in 1000 ml double distilled water). Immediately the plates were read at 550 nm and 610 nm and the ratio OD 550/610 was measured. Dilutions of purified chondroitinsulfate were used as standard.

## 5 Results

As a first assessment, the four experimental diets were compared to the control diet. The results are presented in Table 1 below.

Glycosaminoglycan concentration (microg/ml)		
Diets	Average (microg/ml)	Standard deviation (microg/ml)
A2 - control	1.07	± 0.05
C2 - antioxidant cocktail	1.34	± 0.04
D2 - carnitine + antioxidant cocktail	1.46	± 0.03
E2 - Gingko extract	1.59	± 0.09
F2 - carnitine	1.42	± 0.09

10

It has thus been showed that dietary intervention for 3 month stimulates glycosaminoglycan content in skin in diets C2, D2, E2, and F2. A2 corresponds to the control group.

15

### Example 2: Dry pet food

A feed mixture is made up of about 58% by weight of corn, about 5.5% by weight of corn gluten, about 22% by weight of chicken meal, 2,5% dried chicory, 1% carnitine, 0.1% Vit C, vit E (150 IU / kg), 0,05%grape seed proanthocyanidin extract and 1% cysteine as antioxidant, salts, vitamins and minerals making up the remainder.

20

The feed mixture is fed into a preconditioner and moistened. The moistened feed is then fed into an extruder-cooker and gelatinised. The gelatinised matrix leaving the extruder is forced through a die and extruded. The extrudate is cut into

25

pieces suitable for feeding to dogs, dried at about 110°C for about 20 minutes, and cooled to form pellets.

This dry dog food is able to improve the skin quality in dogs.

5

### **Example 3: Dry pet food**

10 A feed mixture is prepared as in example 1, using 2% carnitine and 0.05% ginkgo biloba extract as antioxidant. Then, the feed mixture is processed as in example 1. The dry dog food is particularly intended to improve or restore the age-related skin alterations in dogs.

### **Example 4: Nutritional formula**

15 A nutritional composition is prepared, and which contains for 100 g of powder: 15 % of protein hydrolysate, 25 % of fats, 55 % carbohydrates (including maltodextrin 37 %, starch 6 %, sucrose 12 %), traces of vitamins and oligoelements to meet daily requirements, 2 % minerals and 3 % moisture and 2% pyruvate and 1% carnosine or carnosine precursor as antioxidant.

20

13 g of this powder is mixed in 100 ml of water. The obtained formula is particularly intended for improving skin quality and preventing skin age-related alterations in humans.

### **Example 5: Oral supplement**

25 A daily orally administrable composition for improving skin quality, in particular that stimulates glycosaminoglycan production and deposition in skin contains 240 mg of Ginkgo biloba extract and Glucidex IT 19 (maltodextrin powder)  
30 QSP 500 mg.

The composition provides a protective and preventive effect on the alterations of the skin, in particular due to aging process.

## Claims

1. An orally administrable composition for improving skin quality and prevent or restore age-related alterations of skin in humans or animals, which comprises as  
5 an active ingredient an effective amount of a molecule that stimulates energy metabolism of the cell or an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier.
2. A composition according to claim 1, wherein said molecule is L-carnitine,  
10 creatine, fatty acids (monounsaturated and polyunsaturated, particularly omega-3 fatty acids), cardiolipin, nicotinamide or carbohydrate and natural sources thereof.
3. A composition according to claim 1 or 2, in which the antioxidant is a source  
15 of thiols such as lipoic acid, cysteine, cystine, methionine, S-adenosyl-methionine, taurine, glutathione or natural sources thereof, or a compound that upregulate their biosynthesis in vivo, or other antioxidants such as vitamin C, vitamin E, carotenoids, ubiquinones, tea catechins, coffee extracts containing polyphenols and/or diterpenes, grape or grape seed extracts rich in proanthocyanidins, spice extracts, soy extracts and other sources of flavonoids with antioxidant activity or compounds such as  
20 ursodeoxycholic acid, ursolic acid, ginseng and gingenosides and natural sources thereof.
4. A composition according to any of claims 1 to 3, which is a pharmaceutical  
25 composition, a nutritionally complete pet food or a dietary supplement for animal consumption.
5. A composition according to any of claims 1 to 3, which is a pharmaceutical  
composition, a nutritionally complete human food, or a dietary supplement for  
human consumption.  
30
6. A composition according to any of claims 1 to 5, which stimulates extracellular matrix production, in particular synthesis of glycosaminoglycans that bind interstitial fluid and improve skin turgor.

7. A composition according to one of claims 1 to 6, which comprises carnitine or ginkgo extract or antioxydants or combinatory admixtures thereof.

5 8. Use of a molecule that stimulates energy metabolism of the cell, an antioxidant or a combination thereof, for the preparation of an orally administrable composition intended to improve skin quality in humans or animals, in particular skin turgor.

10 9. Use of a molecule that stimulates energy metabolism of the cell or an antioxidant or a combination thereof, for the preparation of an orally administrable composition intended to prevent or restore skin age-related alterations in humans or animals.

15 10. A method to improve skin quality of humans or animals, comprising administering to the individual a composition according to one of claims 1 to 6.

20 11. A method to prevent or restore skin age-related alterations in humans or animals, comprising administering to the individual a composition according to one of claims 1 to 6.

**Abstract****Orally administrable composition for improving skin quality**

5 The present invention relates to an orally administrable composition for improving skin quality and prevent or restore age-related alterations of skin in humans or animals, which comprises as an active ingredient an effective amount of a molecule that stimulates energy metabolism of the cell or an antioxidant or combinatory admixtures thereof, in an orally acceptable carrier.

10



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ **BLACK BORDERS**

☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☐ **FADED TEXT OR DRAWING**

☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**